Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients
- 7 June 2023
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (11) , 1499-1501
Abstract
No abstract availableKeywords
Funding Information
- Capital's Fund's for Health Improvement and Researc
- National Regional Medical Center Opening Projec
This publication has 5 references indexed in Scilit:
- Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositisBrain, 2019
- A child with severe juvenile dermatomyositis treated with ruxolitinibBrain, 2018
- Identification of Citrullinated Hsp90 Isoforms as Novel Autoantigens in Rheumatoid Arthritis–Associated Interstitial Lung DiseaseArthritis & Rheumatism, 2013
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trialArthritis & Rheumatism, 2012
- The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective studyJournal of the American Academy of Dermatology, 2011